                         SEQUENCE LISTING

<110>  Ironwood Pharmaceuticals, Inc.
       Currie, Mark  G.
       Zimmer, Daniel P.
       Fretzen, Angelika
       Kessler, Marco
 
<120>  Treatments for Gastrointestinal Disorders

<130>  223355/083PCT1/327407

<140>  PCT/US12/tbd
<141>  2012-05-08

<150>  US 61/485,046
<151>  2011-05-11

<160>  10    

<170>  PatentIn version 3.5

<210>  1
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetically generated peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa1 is Asn, D-Asn, Gln, D-Gln, Pro, Ala, beta-Ala, D-Ala, Val, 
       D-Val, Gly, Thr, D-Thr, Asp, D-Asp, gamma-carboxylated Asp, Glu, 
       D-Glu, gamma-carboxylated Glu, a-aminosuberic acid (Asu), 
       a-aminoadipic acid (Aad), a-aminopimelic acid (Apm), or is absent

<220>
<221>  VARIANT
<222>  (1)..(2)
<223>  if Xaa1 is absent and Xaa2 is present, then Xaa2 may be modified 
       on its amino group by methyl, ethanedioic acid, propanedioic 
       acid, butanedioic acid, pentanedioic acid, hexanedioic acid, 
       heptanedioic acid or octanedioic acid

<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  Xaa1 is present, Xaa1 may be modified on its amino acid group by 
       methyl, ethanedioic acid, propanedioic acid, butanedioic acid, 
       pentanedioic acid, hexanedioic acid, heptanedioic acid or 
       octanedioic acid

<220>
<221>  VARIANT
<222>  (1)..(3)
<223>  if both Xaa1 and Xaa2 are absent, then Xaa3 may be modified on 
       its amino group by methyl, ethanedioic acid, propanedioic acid, 
       butanedioic acid, pentaneioic acid, hexanedioic acid, 
       heptanedioic acid or octanedioic acid

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa2 is Asp, gamma-carboxylated Asp, Glu, gamma-carboxylated Glu,
       Asu, Aad, Apm, or is absent

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa3 is Asp, gamma-carboxylated Asp, Glu, gamma-carboxylated Glu,
       Asu, Aad, Apm or is absent

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa4 is Cys or D-Cys

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa6 is P-Ser, P-Thr, P-homo-Ser, 4-hydroxyvaline phosphate, 
       P-homo-Thr, P-Cys or P-Tyr

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa7 is Tyr, Leu, Phe or Ile

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa is Cys or D-Cys

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  Xaa14 is Thr, Ala or Phe

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa16 is Cys or D-Cys

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa17 is Tyr, D-Tyr, or is absent

<400>  1

Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys Asn Pro Ala Cys Xaa Gly Xaa 
1               5                   10                  15      


Xaa 
    


<210>  2
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetically generated peptide


<220>
<221>  MOD_RES
<222>  (5)..(5)
<223>  Xaa6 is P-Ser

<400>  2

Asp Asp Cys Cys Xaa Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 
1               5                   10                  15      


<210>  3
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetically generated peptide


<220>
<221>  MOD_RES
<222>  (5)..(5)
<223>  Xaa5 is P-Ser

<400>  3

Asp Asp Cys Cys Xaa Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys 
1               5                   10                  15  


<210>  4
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetically generated peptide


<220>
<221>  MOD_RES
<222>  (5)..(5)
<223>  Xaa5 is P-Ser

<400>  4

Asp Asp Cys Cys Xaa Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 
1               5                   10                  15      


<210>  5
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetically generated peptide


<220>
<221>  MOD_RES
<222>  (5)..(5)
<223>  Xaa5 is P-Ser

<400>  5

Asp Asp Cys Cys Xaa Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys 
1               5                   10                  15  


<210>  6
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetically generated peptide


<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Xaa3 is P-Ser

<400>  6

Cys Cys Xaa Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 
1               5                   10                  


<210>  7
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetically generated peptide


<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Xaa3 is P-Ser

<400>  7

Cys Cys Xaa Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys 
1               5                   10              


<210>  8
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetically generated peptide


<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Xaa3 is P-Ser

<400>  8

Cys Cys Xaa Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 
1               5                   10                  


<210>  9
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetically generated peptide


<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Xaa3 is P-Ser

<400>  9

Cys Cys Xaa Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys 
1               5                   10              


<210>  10
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetically generated peptide


<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Xaa3 is P-Ser

<220>
<221>  VARIANT
<222>  (4)..(4)
<223>  Xaa4 is Tyr or Leu

<220>
<221>  VARIANT
<222>  (14)..(14)
<223>  Xaa14 is Tyr

<400>  10

Cys Cys Xaa Xaa Cys Cys Asn Pro Ala Cys Thr Gly Cys Xaa 
1               5                   10                  


